Zygomycosis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:73263B46.0B46.1B46.2
Who is this for?
Show terms as
1FDA treatments6Active trials17Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Zygomycosis, also called mucormycosis (its most common form), is a serious fungal infection caused by a group of molds called Zygomycetes. These molds are found in the environment — in soil, decaying leaves, compost, and rotting food — and most healthy people are never harmed by them. However, in people whose immune systems are weakened or who have certain health conditions like uncontrolled diabetes, the fungus can invade the body and cause life-threatening illness. The infection can affect many parts of the body. The most common form starts in the sinuses and can spread to the face, eyes, and brain. It can also infect the lungs, skin, stomach and intestines, or spread throughout the entire body (called disseminated infection). The fungus damages tissue by blocking blood vessels, which cuts off blood supply and causes tissue to die. This is why dark or blackened tissue around the nose, eyes, or mouth is a major warning sign. Treatment requires urgent action and usually involves a combination of antifungal medications — most commonly amphotericin B — and surgery to remove infected tissue. Controlling the underlying condition, such as bringing blood sugar under control in diabetes, is also a critical part of treatment. Even with aggressive treatment, zygomycosis can be fatal, especially when diagnosed late. Early recognition and rapid treatment give the best chance of survival.

Also known as:

Key symptoms:

Facial pain or swelling, especially around the sinuses, nose, or eyesBlack or darkened tissue on the face, inside the nose, or around the mouthStuffy or blocked nose with dark or bloody dischargeFever that does not go awayHeadacheBlurred or double vision, or loss of visionDrooping eyelid or bulging eyeChest pain or difficulty breathing (when lungs are affected)Coughing up bloodSkin wounds that turn black and do not healStomach pain, nausea, or vomiting (when gut is affected)Confusion or altered mental state (when brain is involved)

Clinical phenotype terms (50)— hover any for plain English
Unusual skin infectionHP:0032162Periorbital fullnessHP:0000629Nasal congestionHP:0001742KetoacidosisHP:0001993
Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

8 events
Sep 2025Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project

M.D. Anderson Cancer Center

TrialNOT YET RECRUITING
Sep 2025Chest CT Scan in Pulmonary Mucormycosis: Prognostic Value

University Hospital, Strasbourg, France

TrialRECRUITING
May 2025Amphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety Study

Qiu Ye

TrialACTIVE NOT RECRUITING
Mar 2025Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety

Institute of Hematology & Blood Diseases Hospital, China

TrialRECRUITING
Jan 2025Antifungal Drugs in Pulmonary Mucormycosis

Bin Cao — PHASE4

TrialNOT YET RECRUITING
Feb 2024Rehabilitation With an Obturator in Maxillary Defects

Menoufia University

TrialACTIVE NOT RECRUITING
Nov 2023Biomarkers for Invasive Mucormycosis

University Hospital, Lille

TrialRECRUITING
Jul 2022Amphotericin Versus Posaconazole for Pulmonary Mucormycosis

Post Graduate Institute of Medical Education and Research, Chandigarh — PHASE2

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

Cresemba

isavuconazonium sulfate· Astellas Pharma Global Development Inc.

CRESEMBA is indicated for the treatment of invasive mucormycosis

Clinical Trials

6 recruitingView all trials with filters →
Phase 21 trial
Amphotericin Versus Posaconazole for Pulmonary Mucormycosis
Phase 2
Actively Recruiting
· Sites: Chandigarh, Chandigarh · Age: 1399 yrs
Other5 trials
Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety
Actively Recruiting
PI: Sizhou Feng (Institute of Hematology & Blood Diseases Hospital,) · Sites: Dalian; Harbin +7 more · Age: 1865 yrs
Amphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety Study
Active
· Sites: Nanning, Guangxi
Rehabilitation With an Obturator in Maxillary Defects
Active
PI: Mohammed A. Elsawy, PhD (Menoufia University) · Sites: Al Mansurah · Age: 3070 yrs
Chest CT Scan in Pulmonary Mucormycosis: Prognostic Value
Actively Recruiting
· Sites: Strasbourg · Age: 1899 yrs
Biomarkers for Invasive Mucormycosis
Actively Recruiting
PI: Marjorie CORNU, MD (University Hospital, Lille) · Sites: Lille, Hauts-de-France · Age: 364 yrs

Specialists

17 foundView all specialists →
MM
Marjorie CORNU, MD
Specialist
PI on 1 active trial
SF
Sizhou Feng
Specialist
PI on 2 active trials
RM
Ratnakara Rao, MBBS, MD
Specialist
PI on 1 active trial
MP
Mohammed A. Elsawy, PhD
Specialist
PI on 1 active trial
RM
Romaric Larcher, MD, PharmD, MSc
Specialist
PI on 1 active trial
AM
Ahmad Ahmad, Master
Specialist
PI on 1 active trial
AP
Ali Khalil, PHD
Specialist
PI on 1 active trial
JP
Juan Wu, PhD
Specialist
PI on 1 active trial
BM
Brad Spellberg, MD
TORRANCE, CA
Specialist
PI on 1 active trial
OP
Olivier Lortholary, MD, PhD
Specialist
PI on 5 active trials
ED
Executive Director
Specialist
PI on 2 active trials
AM
Ayman Sadek, MD
MONROVIA, CA
Specialist
PI on 1 active trial
EG
Eslam A Gharieb
Specialist
PI on 1 active trial
BC
Bin Cao
Specialist
PI on 1 active trial
HY
Hekmat Yacoub
Specialist
PI on 1 active trial
ML
Manting Liu
Specialist
PI on 1 active trial
MP
Mohsen Pourazizi
Specialist
PI on 2 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Zygomycosis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open ZygomycosisForum →

No community posts yet. Be the first to share your experience with Zygomycosis.

Start the conversation →

Latest news about Zygomycosis

Disease timeline:

New recruiting trial: Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety

A new clinical trial is recruiting patients for Zygomycosis

New recruiting trial: Chest CT Scan in Pulmonary Mucormycosis: Prognostic Value

A new clinical trial is recruiting patients for Zygomycosis

New recruiting trial: Amphotericin Versus Posaconazole for Pulmonary Mucormycosis

A new clinical trial is recruiting patients for Zygomycosis

New recruiting trial: Biomarkers for Invasive Mucormycosis

A new clinical trial is recruiting patients for Zygomycosis

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.How far has the infection spread, and what organs are affected?,What antifungal medication will I receive, and how long will treatment last?,Do I need surgery, and if so, what tissue will be removed and what will the impact be?,What is causing my immune system to be vulnerable, and how can we address that underlying condition?,What are the signs that the infection is getting worse or coming back, and when should I go to the emergency room?,Are there clinical trials or newer treatments I might be eligible for?,What support services are available for recovery, including reconstructive surgery or mental health support?

Common questions about Zygomycosis

What is Zygomycosis?

Zygomycosis, also called mucormycosis (its most common form), is a serious fungal infection caused by a group of molds called Zygomycetes. These molds are found in the environment — in soil, decaying leaves, compost, and rotting food — and most healthy people are never harmed by them. However, in people whose immune systems are weakened or who have certain health conditions like uncontrolled diabetes, the fungus can invade the body and cause life-threatening illness. The infection can affect many parts of the body. The most common form starts in the sinuses and can spread to the face, eyes, a

How is Zygomycosis inherited?

Zygomycosis follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Are there clinical trials for Zygomycosis?

Yes — 6 recruiting clinical trials are currently listed for Zygomycosis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Zygomycosis?

17 specialists and care centers treating Zygomycosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.